An evidence based clinical overview for plastic surgeons
Why surgical scar optimisation belongs in the treatment pathway
For plastic surgeons, the scar is not a secondary endpoint. It is part of the operation’s functional and aesthetic result. Even a technically sound closure can mature into a raised, erythematous, tethered, widened or texturally conspicuous scar. The biological trajectory is influenced by tension, inflammation, infection, anatomical location, genetic predisposition, phototype and patient behaviour. No energy-based procedure can compensate for poor wound closure, active infection or unaddressed mechanical tension. Once epithelial integrity is secure, however, fractional ablative CO₂ may be considered as an adjunct within a broader scar-management program. The clinical aim is not to “erase” a scar. It is to reduce contrast between the scar and surrounding skin, soften abnormal collagen architecture, improve pliability and surface texture, and—where appropriate—reduce symptoms such as tightness or pruritus. Expectations should be framed around measurable improvement rather than complete removal.
Why 10,600 nm fractional CO2 can remodel scar tissue
At 10,600 nm, water is the principal chromophore. Absorption produces rapid tissue vaporisation within microscopic treatment columns, surrounded by a controlled zone of thermal coagulation. In fractional delivery, untreated bridges of tissue remain between columns and support re-epithelialisation. The resulting wound-healing response can reorganise collagen, influence extracellular-matrix turnover and improve the biomechanical behaviour of scar tissue over time. Depth and thermal effect are not interchangeable concepts. Pulse energy, spot size, pulse structure, density, number of passes, stacking and scanner behaviour collectively determine the tissue response. A deeper column is not automatically a better scar treatment, and excessive density can convert a fractional procedure into an unnecessarily confluent thermal injury. For postoperative scars, the endpoint should be selected from the phenotype and treatment objective—not from a desire to maximise energy.
What the eCO2 3D platform contributes
Lutronic’s eCO2 family is a fractional 10,600 nm CO₂ platform designed to deliver adjustable ablative resurfacing across a range of depths and densities. Current eCO2 3D manufacturer information describes a 40 W system, interchangeable 120, 300 and 500 micrometre spot options, Static and Dynamic delivery modes, and Controlled Chaos Technology. The manufacturer states that Controlled Chaos randomises the scan sequence to reduce local heat accumulation and hot spots. These are engineering features; they do not substitute for clinical judgement, conservative escalation or appropriate postoperative care.
What the clinical literature shows
Early postoperative scars
In a prospective study of 23 thyroidectomy scars, one fractional CO₂ session delivered 2 to 3 weeks after surgery produced a statistically significant reduction in Vancouver Scar Scale scores; 12 of 23 participants showed greater than 51% clinical improvement at three months. The study was small, involved Korean women and used a single protocol, so it supports feasibility rather than a universal timing or parameter rule. A later prospective split-scar, evaluator-blinded study treated half of 16 postoperative scars beginning three weeks after surgery, with two sessions separated by two weeks. At three months, the treated halves showed a greater reduction in Vancouver Scar Scale score—particularly texture and thickness—and patients preferred the treated side. The within-scar design is clinically useful because it reduces interpatient variability, although the sample and follow-up were limited.
Established and noticeable postsurgical scars
A retrospective evaluation of 40 patients treated for facial scars after skin-cancer surgery reported significant improvement when pre- and postoperative photographs were independently assessed by patients, laypersons and experts. Patient satisfaction was high. The design does not establish superiority over another treatment or natural maturation, but it supports fractional CO₂ as a relevant option for mature, visible facial scars in appropriately selected patients.
Hypertrophic scars
A 2022 systematic review identified five prospective randomised studies of fractional CO₂ for hypertrophic scars. All reported statistically significant improvement using scar scales; transient erythema, oedema, itching or burning were generally tolerated. The authors also highlighted small samples, short follow-up and heterogeneity. This is the correct interpretation for surgical practice: the signal of benefit is consistent, while the evidence is not sufficiently standardised to justify a single protocol for every scar.
A practical surgeon led treatment framework
- Define the scar diagnosis and treatment priority. Document colour, thickness, contour, pliability, adherence, symptoms and functional restriction. Use a validated instrument such as POSAS or the Vancouver Scar Scale where feasible.
- Confirm wound readiness. Do not treat through infection, dehiscence, unstable epithelium, active dermatitis or unexplained delayed healing. Early intervention studies should not be interpreted as permission to treat an incompletely healed wound.
- Assess risk modifiers. Review Fitzpatrick phototype, recent tanning, post-inflammatory hyperpigmentation history, keloid tendency, isotretinoin history in context, immunosuppression, smoking, diabetes, photosensitising medication, HSV history and capacity for aftercare.
- Match modality to the dominant component. Fractional CO₂ is particularly relevant to thickness, texture, stiffness and contracture. Persistent vascular erythema may require a vascular laser strategy. Widening caused by tension or contour distortion may require surgical revision. Keloids commonly require multimodal therapy rather than laser monotherapy.
- Use a staged, phenotype-led plan. Select spot size, energy, density and mode to achieve the required biological effect with the lowest reasonable tissue burden. Consider test areas in higher-risk skin or uncertain sites. Avoid importing parameters across devices.
- Standardise imaging and outcomes. Use fixed lighting, camera, distance, angle and patient position. Record baseline and serial scar scores, symptoms, adverse events and patient satisfaction. Photography requires explicit consent for clinical use and separate consent for marketing or publication.
- Review the response before escalating. Collagen remodelling continues between visits. Escalation should follow clinical response and healing, not a preset assumption that every session must be stronger.
How eCO2 3D may fit with other scar interventions
Fractional CO₂ is often most useful within a multimodal plan. Silicone gel or sheeting, taping and tension reduction remain foundational in suitable wounds. Vascular lasers may better address persistent erythema. Intralesional corticosteroid, 5-fluorouracil or other scar-directed therapies may be appropriate for hypertrophic scars or keloids under medical protocols. Surgical revision remains necessary when scar geometry, malposition, dog-ears, contour deformity or persistent tension cannot be corrected with energybased treatment. Laser-assisted drug delivery deserves particular caution. Fractional ablation increases cutaneous permeability, but evidence for a particular drug, concentration, vehicle and scar type cannot be generalised automatically. It may also represent off-label use. Drug choice, sterility, dosing, systemic exposure, occlusion and medico-legal documentation require an explicit surgeon-led protocol.
Safety considerations that should be built into the protocol
• Eye safety: wavelength-appropriate eyewear for the patient and every person in the controlled area; metal corneal shields only when clinically indicated and used by appropriately trained practitioners.
• Laser plume: use effective smoke evacuation close to the source, appropriate filtration, room controls and personal protective measures. Surgical masks alone are not plume evacuation.
• Fire prevention: remove flammable preparation residue, manage oxygen-rich environments, protect hair and drapes, and maintain a clear laser fire response plan.
• Infection prevention: aseptic technique, single-use items where applicable, clean device contact components and a written post-treatment wound-care pathway.
• Pigmentary risk: counsel regarding post-inflammatory hyperpigmentation and hypopigmentation, particularly in higher phototypes; use strict photoprotection and consider conservative test treatment.
• Delayed healing and scarring: avoid excessive overlap, stacking or density; provide rapid review for escalating pain, purulence, vesiculation, prolonged erythema or delayed re-epithelialisation.
Counselling patients accurately
A consent discussion should explain that improvement is gradual and variable. Multiple sessions may be required. Expected effects include erythema, oedema, warmth, pinpoint crusting or exudation and a temporary change in texture. Relevant risks include infection, HSV reactivation, acneiform eruption, milia, prolonged erythema, pigment alteration, demarcation, delayed healing and worsening or new scarring. Patients should understand that a mature scar cannot be returned to uninjured skin and that revision surgery or combined modalities may still be required.
Clinical conclusion
For plastic surgeons the Cynosure Lutronic eCO2 3D offers a configurable fractional ablative CO₂ platform that can be incorporated into early scar optimisation or the treatment of established postsurgical scars. Its clinical value lies in controlled remodelling, not simply aggressive resurfacing. The best candidates have a clearly defined scar problem, stable epithelial healing, realistic expectations and the capacity to follow wound-care and photoprotection instructions. The best protocols are conservative, staged, documented and integrated with mechanical, vascular, injectable or surgical strategies when those better address the scar phenotype. The published literature supports improvement in selected postoperative and hypertrophic scars, but it remains heterogeneous. Device-specific marketing claims should therefore be kept separate from independent clinical evidence, and all treatment parameters should be individualised within the applicable eCO2 instructions for use and formal clinical training.
Selected peer reviewed references
- Jung JY, Jeong JJ, Roh HJ, et al. Early postoperative treatment of thyroidectomy scars using a fractional carbon dioxide laser. Dermatol Surg. 2011;37(2):217-223. doi:10.1111/j.1524-4725.2010.01853.x Link
- Lee SH, Zheng Z, Roh MR. Early postoperative treatment of surgical scars using a fractional carbon dioxide laser: a split-scar, evaluator-blinded study. Dermatol Surg. 2013;39(8):1190-1196. doi:10.1111/dsu.12228 Link
- Wyss N, Graf N, Hafner J, Imhof L. Fractional CO2 laser to improve noticeable scars after skin cancer surgery: an appraisal by the patients, laypersons, and experts. Dermatol Ther. 2021;34:e14999. doi:10.1111/dth.14999 Link
- Simbolon Sitohang IB, Sirait SAP, Safira FD. Fractional carbon dioxide laser for treating hypertrophic scars: a systematic review of randomised trials. Australas J Dermatol. 2022;63:27-35. doi:10.1111/ajd.13730 Link
- Ozog DM, Liu A, Chaffins ML, et al. Evaluation of clinical results, histological architecture, and collagen expression following treatment of mature burn scars with a fractional carbon dioxide laser. JAMA Dermatol. 2013;149(1):50-57. doi:10.1001/2013.jamadermatol.668 Link
- Anderson RR, Donelan MB, Hivnor C, et al. Laser treatment of traumatic scars with an emphasis on ablative fractional laser resurfacing: consensus report. JAMA Dermatol. 2014;150(2):187-193. doi:10.1001/jamadermatol.2013.7761 Link
- Kim J, et al. Comparative efficacy of fractional CO2 laser combined with topical steroid cream versus solution for post-thyroidectomy scar treatment: a prospective study. Healthcare. 2024;12(16):1605. doi:10.3390/healthcare12161605 Link
Manufacturer technical resources and clinical paper library
• Cynosure Lutronic Australia. eCO2 3D product information: system features, delivery modes, spot sizes and intended-use statements. Access resource
• Cynosure Lutronic Australia. eCO2 Plus clinical articles library: peer-reviewed publications associated with the platform and fractional CO2 applications. Access resource
• Lutronic United States. eCO2 Plus provider product information and Controlled Chaos Technology overview. Access resource Evidence note. Manufacturer technical materials are useful for device specifications and platform operation but are not equivalent to independent systematic reviews or randomised comparative trials. Verify the current local instructions for use, regulatory status and approved indications before publishing treatment claims.
